ArticleExperimental and therapeutic medicine2019

Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.

Jian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.